Hikma updates Generics guidance for 2022
This announcement contains inside information.
London, 5 May 2022 - Hikma Pharmaceuticals PLC (Hikma ) notes Jazz Pharmaceuticals' (Jazz) update to its expectations for the launch timing of an authorized generic of Xyrem® (sodium oxybate) as provided in its first quarter 2022 earnings conference call on 4 May 2022. Jazz now expects authorized generic entry to occur "in late 2022, or possibly even January 2023".
As background, in 2017 Hikma entered into a settlement agreement with Jazz to sell an authorized generic of Xyrem®. Under the terms of this agreement, Hikma has a date certain launch of 1 January 2023, or earlier depending on certain market conditions, and 180 days exclusivity.
To align with Jazz's updated expectations, Hikma now conservatively assumes it will launch its authorized generic on 1 January 2023 and that the revenue and profit contribution from the exclusivity period will shift to the first half of 2023. Reflecting this, Hikma is today updating guidance for its Generics business.
For 2022, Hikma now expects Generics revenue to be in the range of $710 million to $750 million and core operating margin to be around 20%, with the lower end of the range reflecting the possibility of further price erosion in the US generic market, should this materialize. This compares with Hikma's previous guidance of Generics revenue growth in the range of 8% to 10% over full year 2021 revenue of $820 million and core operating margin in the range of 24% to 25%.
All other guidance remains unchanged.
-- ENDS -
The person responsible for the release of this announcement on behalf of Hikma is Peter Speirs (Company Secretary).
Enquiries :
Hikma (Investors)
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 7776 477050 |
|
Guy Featherstone Senior Investor Relations Manager |
+44 (0)20 3892 4389/ +44 7795 896738 |
|
Layan Kalisse Investor Relations Analyst |
+44 (0)20 7399 2788/ +44 7970 709912 |
|
Teneo (Press) Charles Armitstead Camilla Cunningham |
+ 44 (0) 7703 330269 + 44 (0) 7464 982426 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2022 Hikma Pharmaceuticals PLC. All rights reserved.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 minute ago British American Tobacco
- 18 minutes ago CC Japan Income & Growth Trust
- 39 minutes ago 3i Infrastructure
- 45 minutes ago QinetiQ Group
- 1 hour ago JPMorgan Emerging Markets Growth & Income plc